DE3334751A1 - Mittel zur diagnose und therapie von malignen tumoren, ein verfahren zu seiner herstellung und seine verwendung sowie die verwendung beschickter liposomen fuer die diagnose und therapie maligner tumoren - Google Patents

Mittel zur diagnose und therapie von malignen tumoren, ein verfahren zu seiner herstellung und seine verwendung sowie die verwendung beschickter liposomen fuer die diagnose und therapie maligner tumoren

Info

Publication number
DE3334751A1
DE3334751A1 DE19833334751 DE3334751A DE3334751A1 DE 3334751 A1 DE3334751 A1 DE 3334751A1 DE 19833334751 DE19833334751 DE 19833334751 DE 3334751 A DE3334751 A DE 3334751A DE 3334751 A1 DE3334751 A1 DE 3334751A1
Authority
DE
Germany
Prior art keywords
liposomes
diagnosis
aldehyde
therapy
malignant tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19833334751
Other languages
German (de)
English (en)
Other versions
DE3334751C2 (https=
Inventor
Udo Dr. 8400 Regensburg Ehrenfeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19833334751 priority Critical patent/DE3334751A1/de
Priority to DE19833336583 priority patent/DE3336583A1/de
Priority to US06/557,738 priority patent/US4590060A/en
Priority to AT89116295T priority patent/ATE159858T1/de
Priority to DE3486459T priority patent/DE3486459D1/de
Priority to AT84110118T priority patent/ATE59966T1/de
Priority to EP84110118A priority patent/EP0142641B1/de
Priority to DE8484110118T priority patent/DE3483949D1/de
Priority to EP89116295A priority patent/EP0350973B1/de
Priority to ZA847296A priority patent/ZA847296B/xx
Priority to AU33327/84A priority patent/AU560178B2/en
Priority to DD84267559A priority patent/DD222783A5/de
Priority to DK455384A priority patent/DK168755B1/da
Priority to KR1019840005894A priority patent/KR910005408B1/ko
Priority to CA000463991A priority patent/CA1234754A/en
Priority to JP59202859A priority patent/JPS60155123A/ja
Publication of DE3334751A1 publication Critical patent/DE3334751A1/de
Application granted granted Critical
Publication of DE3334751C2 publication Critical patent/DE3334751C2/de
Priority to US07/485,757 priority patent/US5021234A/en
Priority to HK931/91A priority patent/HK93191A/xx
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A61K31/115—Formaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE19833334751 1983-09-26 1983-09-26 Mittel zur diagnose und therapie von malignen tumoren, ein verfahren zu seiner herstellung und seine verwendung sowie die verwendung beschickter liposomen fuer die diagnose und therapie maligner tumoren Granted DE3334751A1 (de)

Priority Applications (18)

Application Number Priority Date Filing Date Title
DE19833334751 DE3334751A1 (de) 1983-09-26 1983-09-26 Mittel zur diagnose und therapie von malignen tumoren, ein verfahren zu seiner herstellung und seine verwendung sowie die verwendung beschickter liposomen fuer die diagnose und therapie maligner tumoren
DE19833336583 DE3336583A1 (de) 1983-09-26 1983-10-07 Erzeugnis zur diagnose und therapie von malignen tumoren
US06/557,738 US4590060A (en) 1983-09-26 1983-12-02 Agent facilitating liposome cellular wall transport, a method for the production thereof and its use
EP89116295A EP0350973B1 (de) 1983-09-26 1984-08-24 Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
DE3486459T DE3486459D1 (de) 1983-09-26 1984-08-24 Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
AT84110118T ATE59966T1 (de) 1983-09-26 1984-08-24 Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
EP84110118A EP0142641B1 (de) 1983-09-26 1984-08-24 Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
DE8484110118T DE3483949D1 (de) 1983-09-26 1984-08-24 Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
AT89116295T ATE159858T1 (de) 1983-09-26 1984-08-24 Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr
ZA847296A ZA847296B (en) 1983-09-26 1984-09-17 Agent and product for the diagnosis and treatment of tumors and for the treatment of weaknesses of the cellular and humoral immune defense
AU33327/84A AU560178B2 (en) 1983-09-26 1984-09-20 Liposomes as carrier for immune modulators
DD84267559A DD222783A5 (de) 1983-09-26 1984-09-24 Verfahren zur herstellung eines antitumormittels
DK455384A DK168755B1 (da) 1983-09-26 1984-09-24 Farmaceutisk præparat til diagnose og terapi af tumorer samt til behandling af svækkelser af celle- og humoral-immunforsvar
KR1019840005894A KR910005408B1 (ko) 1983-09-26 1984-09-25 암 진단 및 세포와 체액 면역 방어기능 약화 치료제의 제조방법
CA000463991A CA1234754A (en) 1983-09-26 1984-09-25 Agent and product for the diagnosis and treatment of tumors and for the treatment of weaknesses of the cellular and humoral immune defense
JP59202859A JPS60155123A (ja) 1983-09-26 1984-09-26 癌の診断・治療剤と製品、ならびに細胞及び体液性免疫防御の低能の治療剤と製品
US07/485,757 US5021234A (en) 1983-09-26 1990-02-26 Agent and product for the diagnosis and treatment of tumors and for the treatment of weaknesses of the cellular and humoral immune defense
HK931/91A HK93191A (en) 1983-09-26 1991-11-21 Means and product for the diagnosis and therapy of tumours and for the treatment of weaknesses of the cellular and humoral immune system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833334751 DE3334751A1 (de) 1983-09-26 1983-09-26 Mittel zur diagnose und therapie von malignen tumoren, ein verfahren zu seiner herstellung und seine verwendung sowie die verwendung beschickter liposomen fuer die diagnose und therapie maligner tumoren

Publications (2)

Publication Number Publication Date
DE3334751A1 true DE3334751A1 (de) 1985-04-11
DE3334751C2 DE3334751C2 (https=) 1987-11-19

Family

ID=6210066

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19833334751 Granted DE3334751A1 (de) 1983-09-26 1983-09-26 Mittel zur diagnose und therapie von malignen tumoren, ein verfahren zu seiner herstellung und seine verwendung sowie die verwendung beschickter liposomen fuer die diagnose und therapie maligner tumoren

Country Status (2)

Country Link
DE (1) DE3334751A1 (https=)
ZA (1) ZA847296B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3510795C2 (de) 1985-03-25 1987-04-30 Udo Dr.med. 8400 Regensburg Ehrenfeld Verfahren zur Herstellung eines mikrobiellen Extrakts, das bei dem Verfahren erhaltene Produkt und ein es enthaltendes Arzneimittel
DE3546518C2 (https=) * 1985-03-25 1993-07-15 Udo Dr.Med. 8400 Regensburg De Ehrenfeld
DE3546701C2 (de) * 1985-03-25 1998-01-15 Udo Dr Med Ehrenfeld Diagnostisches Mittel

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310305A (en) * 1977-11-25 1982-01-12 Jacob Frajdenrajch Mechanical device for holding elastic articles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310305A (en) * 1977-11-25 1982-01-12 Jacob Frajdenrajch Mechanical device for holding elastic articles

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
Apple Greenberg, Cancer Chemotherapie 52, 687, 1968 *
ARDENNE, M.v.: Naturwiss. 51, 217, 1964 *
B.E. RYMAN et al.: Biol. of the Cell 47, 71, 1983 *
C. Nielau et al.: Proc. Natl. Acad. Sci. USA 80, 1068, 1983
C. Nielau et al.: Proc. Natl. Acad. Sci. USA, Vol. 80, Page 1068, 1983 *
Cancer Research 32532, 1972, *
EHRENFELDV.: Krebsgeschehen 5, 132, 1979 *
F.M. ROERDINK et al. Biochem. Biophys. Acta 677, 79, 1981 *
G. POSTE et al.: Cancer Res. 39, 881, 1979 *
HUANG C.: Biochemistry 15, 2362, 1969 *
J.I. FIDLER et al.: Cancer Res. 40, 4460, 1980 *
J.I. FIDLER et al.: Cancer Res. 42, 496, 1982 *
M. BUNDGAARD et al.: Ann. Rev. Physiol. 42, 325, 1980 *
M.P.OSBORNEet al.:Int. J. Nucl. Med. Biol. 6, 75, 1979 *
MENDEL, B., Klin. Woschr. 8, 169, 1929BROCK, N., NIELAMP, P.: 2. Krebsforschung 67,1965 *
MOTYCKA, K., LACKO,L.2.Krebsforschung 66, 491, 1965 *
POSTE, G.: Biol. of the Cell 47, 19, 1983 *
V.J.RICHARDSON et al.: Br. J. Cancer 40, 35,1979 *
WARBURG,O., GAHEKA,K., GESSLER,A., LORENZ,S.: 2. Klin. Chemie 1,175, 1963 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3510795C2 (de) 1985-03-25 1987-04-30 Udo Dr.med. 8400 Regensburg Ehrenfeld Verfahren zur Herstellung eines mikrobiellen Extrakts, das bei dem Verfahren erhaltene Produkt und ein es enthaltendes Arzneimittel
DE3546518C2 (https=) * 1985-03-25 1993-07-15 Udo Dr.Med. 8400 Regensburg De Ehrenfeld
DE3546701C2 (de) * 1985-03-25 1998-01-15 Udo Dr Med Ehrenfeld Diagnostisches Mittel

Also Published As

Publication number Publication date
ZA847296B (en) 1985-05-29
DE3334751C2 (https=) 1987-11-19

Similar Documents

Publication Publication Date Title
EP0142641B1 (de) Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
DE3927113C2 (de) Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung
JP2681147B2 (ja) がん性腫瘍転移の治療剤
AT393221B (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken
DE3336583A1 (de) Erzeugnis zur diagnose und therapie von malignen tumoren
EP0810883B1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
EP2015743B1 (de) Glutadon
DE3424781A1 (de) Verwendung von l-carnosin zur tumorbehandlung
DE60222383T2 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
DE69213757T2 (de) Verwendung von kreatinphosphat oder phosphoenolbrenztraubensäure zur behandlung von tumoren
DE3427797A1 (de) Zytoprotektive wirkung von prostacyclin-derivaten an leber, bauchspeicheldruese und niere
DE3334751A1 (de) Mittel zur diagnose und therapie von malignen tumoren, ein verfahren zu seiner herstellung und seine verwendung sowie die verwendung beschickter liposomen fuer die diagnose und therapie maligner tumoren
EP1633394B1 (de) Pharmazeutische kombinationspräparate zur krebstherapie enthaltend glutaminase und antineoplastische anthracycline oder platinverbindungen
DE19744811C2 (de) Verwendung von delta-Aminolävulinsäure zur Herstellung eines topischen Arzneimittels zur integralen Diagnose und/oder Therapie von Tumoren in Hohlorganen
EP1423131B1 (en) Calcium trifluoroacetate with cytotoxic activity
RU2065307C1 (ru) Способ лечения первичного рака печени и набор для лечения первичного рака печени
EP1565176B1 (de) Mittel mit zerstörender wirkung auf maligne tumore sowie verfahren zu seiner herstellung
South-East European Oncology Group (SEEOG) et al. Phase II study of 4′-epi-doxorubicin in patients with untreated, extensive small cell lung cancer
EP1524273A1 (de) Verfahren zur Herstellung von trans- oder cis-Diammoniumdichlorodihydroxoplatin (IV)-Salzen und -Derivaten und ihre Verwendung zur Herstellung von pharmazeutischen Wirkstoffen
DE3229956A1 (de) Arzneimittel mit cytostatischer wirkung
RU2019180C1 (ru) Средство для лечения подкожной фибросаркомы и способ его получения
DE69205776T2 (de) Zusammensetzungen für die Krebstherapie.
DE2226273A1 (de) Pharmazeutische praeparate zur behandlung der osteoporose
DE4228106A1 (de) Verwendung von £-Aminolävulinsäure zur Herstellung eines topischen Arzneimittels zur integralen Diagnose und/oder Therapie von Tumoren in Hohlorganen
EP0788355B1 (de) Verwendung von intravenös applizierbarem eisen zur therapie von tumorerkrankungen und/oder infektionskrankheiten

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
AG Has addition no.

Ref country code: DE

Ref document number: 3336583

Format of ref document f/p: P

Q161 Has additional application no.

Ref document number: 3402312

Country of ref document: DE

AG Has addition no.

Ref country code: DE

Ref document number: 3402312

Format of ref document f/p: P

Ref country code: DE

Ref document number: 3336583

Format of ref document f/p: P

D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee